View Older Stories View More Recent Stories

Dec 1, 2017 10:06AM Amarantus Provides Comprehensive Corporate Update
Nov 17, 2017 07:17AM Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants
Feb 27, 2017 06:14PM Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.
Aug 8, 2016 09:15AM Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
Jun 7, 2016 08:40AM Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
Jun 3, 2016 09:00AM Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results
May 27, 2016 09:52AM Amarantus Announces Upcoming Investor Presentations
May 12, 2016 07:30AM Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health
Apr 25, 2016 08:00AM Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine
Apr 21, 2016 04:02PM Amarantus Announces Capital Infusion
Mar 22, 2016 08:00AM Amarantus Announces Cancellation of Special Meeting of Shareholders
Mar 7, 2016 03:30PM Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination
Mar 7, 2016 08:53AM Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Mar 7, 2016 08:00AM Amarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health
Mar 4, 2016 01:00PM Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board
Feb 29, 2016 07:30AM Amarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders
Feb 22, 2016 06:00AM Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program
Feb 19, 2016 06:37PM Amarantus Announces $3M Capital Infusion
Feb 10, 2016 07:45AM Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Feb 9, 2016 02:23PM Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
Feb 5, 2016 08:30AM Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
Feb 3, 2016 09:00AM Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
Jan 29, 2016 09:00AM Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease
Jan 27, 2016 03:30PM Amarantus Announces $1M Investment
Jan 19, 2016 09:15AM Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
Jan 19, 2016 09:00AM Amarantus Enters into Letter of Intent to Merge Diagnostics Business Unit into Avant Diagnostics
Jan 15, 2016 08:00AM Amarantus to Present at ICV Sonoma Event
Jan 11, 2016 09:00AM Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
Dec 29, 2015 08:00AM Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
Dec 22, 2015 10:41AM Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
Dec 16, 2015 10:56AM Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID
Dec 15, 2015 07:30AM Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)
Dec 14, 2015 08:30AM StockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.
Dec 10, 2015 10:48AM Amarantus Retains WallachBeth Capital to Evaluate Strategic Options for MANF Gene Therapy Program
Dec 8, 2015 08:06AM Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression
Dec 7, 2015 08:30AM Amarantus to Present at ICV Manhattan Event on December 8, 2015
Dec 3, 2015 08:00AM Amarantus to Present at LD Micro Main Event on December 3, 2015
Nov 13, 2015 08:30AM Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
Oct 29, 2015 09:58AM Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease
Oct 26, 2015 08:30AM Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs
Oct 22, 2015 09:15AM Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
Oct 19, 2015 08:00AM Amarantus to Present at BIO Investor Forum 2015
Oct 14, 2015 10:30AM Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns
Oct 8, 2015 08:34AM Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
Oct 6, 2015 08:30AM Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
Oct 5, 2015 10:48AM Amarantus to Present at the 2015 Aegis Growth Conference
Oct 1, 2015 09:25AM Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases
Oct 1, 2015 09:25AM Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases
Oct 1, 2015 07:32AM Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible
Oct 1, 2015 07:32AM Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible
View More Recent Stories View Older Stories